A systematic review published in Frontiers in Nutrition concludes that intermittent fasting performs about as well as ordinary calorie restriction for weight and glucose control, while arguing that its more interesting effects may come from timing rather than energy deficit. The authors, based at Ningbo University and affiliated institutions in Zhejiang, China, screened PubMed and Web of Science through July 31, 2026 and included 76 references.

Intermittent fasting here means four patterns: time-restricted feeding (eating confined to a window of 4 to 12 hours, most commonly 16:8), alternate-day fasting, 5:2 fasting, and 4:3 fasting. The chrononutrition framing is the point of the paper: the claim is not that eating less works, which is established, but that when you eat may act on metabolism through pathways of its own.

Key results

On weight, the review leans on a network meta-analysis of 99 randomized trials which found most fasting regimens produced weight loss comparable to continuous energy restriction at 24 weeks or longer. Across the four patterns, typical reductions ranged from roughly 1.5 kg for time-restricted feeding to 7.7 kg for 4:3, varying with duration and adherence.

Glycemic findings follow the same pattern. Randomized trials reported reductions in fasting glucose, fasting insulin and HbA1c, but two trials by Carter and colleagues found 5:2 and calorie restriction produced nearly identical HbA1c reductions at both 12 weeks and 12 months in patients with diabetes. In NAFLD patients, 16:8 feeding and calorie restriction cut intrahepatic triglyceride by 8.3% and 8.1% respectively at six months.

The adherence number

The most practically useful figure in the paper is not an outcome at all. Time-restricted feeding showed compliance of 85 to 88% at 12 weeks, while long-term adherence to 5:2 fasting fell below 30% over two years, which is a sharper differentiator between protocols than any lipid result in the review.

Limitations

The four proposed mechanisms, gut barrier and GLP-1 expression, circadian gene reprogramming, short-chain fatty acid driven browning of white adipose tissue, and SIRT3-AMPK-mTOR autophagy signaling, rest substantially on rodent studies, and the authors say large randomized trials are needed to validate preclinical findings in diverse populations. Lipid results were inconsistent across trials, few studies isolate timing from energy deficit, and the review notes hypoglycemia and adherence as potential adverse effects requiring individualized clinical approaches.

Bottom line

The authors position fasting as a potentially effective alternative to calorie restriction rather than a superior one, which is a more honest reading than most coverage of this field offers. What remains unsettled is whether any of the chronobiological mechanisms do measurable work in humans once the calorie deficit is matched.